tiprankstipranks
Trending News
More News >
Ajinomoto Co Inc (JP:2802)
:2802
Advertisement

Ajinomoto Co (2802) AI Stock Analysis

Compare
2 Followers

Top Page

JP:2802

Ajinomoto Co

(OTC:2802)

Rating:74Outperform
Price Target:
¥4,451.00
▲(11.55%Upside)
Ajinomoto Co's overall stock score is driven by its strong financial performance and solid technical indicators, despite the overvaluation concerns. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Innovation and Market Dominance
Ajinomoto Co. monopolizes the sale of Ajinomoto Build-up Film (ABF), a critical component in high-end chips, maintaining its dominance through innovation and responsiveness to client demands.
Shareholder Returns
Ajinomoto continues to maintain a shareholder-friendly capital management stance, targeting a total shareholder return of 50% or more through a progressive dividend policy and share buybacks.
Stock Support Actions
The company announced a series of shareholder-friendly corporate actions, including an increase in the FY24F dividend, a share buyback, and a 2 for 1 stock split, likely providing support to the share price.
Negative Factors
AI Capex Reduction Risk
A key downside risk will be an industry-wide cutback on AI capex spend, which will hamper the growth of its functional materials segment, a major growth driver.
Frozen Foods Margin Pressure
Frozen Foods margins have been softening again in FY3/25, with an estimated dip to 3.8%.
Restructuring Concerns
Ajinomoto has announced another round of layoffs in their North America Frozen Food business, signaling that the restructuring agenda continues unabated, despite the abrupt change of Global CEO.

Ajinomoto Co (2802) vs. iShares MSCI Japan ETF (EWJ)

Ajinomoto Co Business Overview & Revenue Model

Company DescriptionAjinomoto Co., Inc. is a global leader in the food, amino acids, and specialty chemicals industries. Established in Japan, the company has expanded its operations worldwide, offering a diverse portfolio that includes seasonings, processed foods, beverages, pharmaceuticals, and nutraceuticals. Ajinomoto is particularly renowned for its pioneering work in the development and commercialization of monosodium glutamate (MSG), which has become a staple in enhancing food flavors. The company operates through several segments, focusing on food products, amino acids for pharmaceuticals and health care, and specialty chemicals, thereby catering to a wide range of consumer and industrial needs.
How the Company Makes MoneyAjinomoto Co., Inc. generates revenue through a multi-faceted business model that leverages its expertise in biotechnology and food science. The company's primary revenue streams include the sale of seasonings and processed foods, where it holds a strong market presence due to its popular products such as 'AJI-NO-MOTO' seasoning. Additionally, Ajinomoto capitalizes on its amino acids business, supplying essential amino acids to the pharmaceutical, nutraceutical, and animal nutrition industries. The specialty chemicals segment also contributes to its earnings, offering products used in electronic materials and cosmetics. Strategic partnerships and investments in research and development further enhance its ability to innovate and maintain a competitive edge across its sectors.

Ajinomoto Co Earnings Call Summary

Earnings Call Date:May 08, 2025
(Q3-2024)
|
% Change Since: 32.78%|
Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed sentiment with record-high sales and strong segment performance in seasonings and frozen foods, but significant challenges in healthcare, biopharma services, and the impact of the Forge acquisition. The company's strategic initiatives and new product successes provide optimism for future growth, yet current challenges weigh on the overall sentiment.
Q3-2024 Updates
Positive Updates
Record-High Q3 Sales and Business Profits
Q3 sales and business income reached record highs for both the 9-month period and the quarter. Sales were JPY 1.676 billion, 104% of the previous year's level, and business profit was JPY 124.4 billion, 104.4% of the previous year.
Strong Performance in Seasonings and Foods
Seasonings and foods achieved strong profit growth, almost meeting the full year profit increase forecast. Domestic and overseas sales were driven by price increases and recovery in volume.
Frozen Food Business Success
The frozen food business achieved more than JPY 10 billion in business profit, surpassing the target within the 9-month period of this fiscal year.
Innovative Product Launches
New personalized interactive communication strategy products, such as Cooked Tofu Kiwami premium Mala Mapo Tofu and women-targeted nutritious meals, have been successful in attracting new customer bases.
Negative Updates
Challenges in Health Care and Other Segments
Profit continues to decrease in every segment of health care and others, with an expectation of bottoming out in the fourth quarter.
Biopharma Services Underperformance
Biopharma services experienced a decline due to decreased orders from biopharmaceutical companies, largely impacted by higher interest rates in North America.
Impact of Forge Biologics Acquisition
The acquisition of Forge Biologics is expected to have a negative impact on profits in Q4 and fiscal '24, with anticipated costs in single-digit billions of yen.
Althea's Decline in Sales and Profits
Althea recorded a decrease in both sales and profits due to a decline in orders from its customers, with plans to recover growth trajectory together with Forge.
Company Guidance
During the Q3 2024 earnings call for 2802.T, the company reported record-high sales and business income for the nine-month period, with sales reaching JPY 1.676 billion, which is 104% of the previous year's level, and business profit at JPY 124.4 billion, representing 104.4% of the previous year. Excluding foreign exchange impact, sales increased by 100.6%, and business profit by 100.3%. The seasonings and foods, along with frozen foods segments, showed significant growth, with overseas volume at 102% and domestic at 99%. However, healthcare and other segments faced declines, with the company anticipating a recovery in electronic materials from Q4. The acquisition of Forge Biologics is expected to impact financials from Q4 onwards, with advanced investments leading to a temporary profit reduction. For fiscal 2024, the firm aims for steady profit growth to align with its 2030 roadmap, leveraging improved efficiency and cost reductions across its operations.

Ajinomoto Co Financial Statement Overview

Summary
Ajinomoto Co exhibits strong revenue growth and robust profitability metrics. The company maintains a stable balance sheet with effective debt management and strong cash flow generation, despite minor fluctuations in net income.
Income Statement
85
Very Positive
Ajinomoto Co has demonstrated strong revenue growth over the years, with a notable increase from JPY 1,471 billion in 2021 to JPY 1,531 billion in 2025. The company maintains solid gross and net profit margins, indicating efficient cost management and profitability. EBIT and EBITDA margins are robust, reflecting strong operational performance. However, a slight decline in net income from JPY 87 billion in 2024 to JPY 70 billion in 2025 suggests potential pressure on profitability.
Balance Sheet
78
Positive
The balance sheet of Ajinomoto Co reveals a stable equity position with stockholders' equity increasing from JPY 538 billion in 2020 to JPY 747 billion in 2025. The debt-to-equity ratio has improved, indicating effective debt management, although total debt remains significant. Return on equity has shown some fluctuations but remains healthy. The equity ratio signifies a good proportion of equity financing, providing stability.
Cash Flow
82
Very Positive
Ajinomoto Co exhibits strong operating cash flow, with a consistent upward trajectory, reaching JPY 210 billion in 2025. The free cash flow has also increased significantly, demonstrating effective capital expenditure management. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to reported earnings. The free cash flow to net income ratio suggests strong cash availability for reinvestment and shareholder returns.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.53T1.44T1.36T1.15T1.07T
Gross Profit550.76B511.45B470.39B425.90B406.22B
EBITDA202.91B232.75B226.85B197.67B168.07B
Net Income70.27B87.12B94.06B75.72B59.42B
Balance Sheet
Total Assets1.72T1.77T1.51T1.46T1.43T
Cash, Cash Equivalents and Short-Term Investments164.78B194.19B145.09B169.26B193.69B
Total Debt455.35B442.49B288.56B313.91B350.42B
Total Liabilities907.85B890.43B688.77B717.32B763.44B
Stockholders Equity746.80B814.69B768.68B686.91B620.26B
Cash Flow
Free Cash Flow121.79B96.05B44.59B64.86B79.61B
Operating Cash Flow209.90B168.07B117.64B145.58B165.65B
Investing Cash Flow-77.38B-132.43B-30.09B-61.57B-66.25B
Financing Cash Flow-137.68B-6.75B-111.06B-123.06B-60.39B

Ajinomoto Co Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3990.00
Price Trends
50DMA
3712.76
Positive
100DMA
3348.87
Positive
200DMA
3201.34
Positive
Market Momentum
MACD
75.30
Positive
RSI
65.49
Neutral
STOCH
63.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2802, the sentiment is Positive. The current price of 3990 is above the 20-day moving average (MA) of 3926.20, above the 50-day MA of 3712.76, and above the 200-day MA of 3201.34, indicating a bullish trend. The MACD of 75.30 indicates Positive momentum. The RSI at 65.49 is Neutral, neither overbought nor oversold. The STOCH value of 63.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2802.

Ajinomoto Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$859.60B15.8011.20%2.41%5.96%3.42%
74
Outperform
$3.91T56.008.89%2.05%6.35%-17.08%
73
Outperform
$996.26B15.5713.14%2.05%3.80%14.95%
72
Outperform
$647.05B17.708.78%1.19%4.25%4.06%
71
Outperform
$1.29T20.5112.17%1.58%7.29%9.73%
67
Neutral
¥844.83B16.466.71%3.25%4.39%2.40%
65
Neutral
£10.65B8.413.35%298.68%-1.40%17.93%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:2802
Ajinomoto Co
3,990.00
934.42
30.58%
JP:2875
Toyo Suisan Kaisha
9,911.00
630.52
6.79%
JP:2897
Nissin Foods Holdings Co
2,905.00
-1,336.58
-31.51%
JP:2269
Meiji Holdings Co
3,076.00
-570.54
-15.65%
JP:2212
Yamazaki Baking Co
3,214.00
-391.61
-10.86%
JP:2801
Kikkoman
1,346.00
-561.99
-29.45%

Ajinomoto Co Corporate Events

Ajinomoto Co. Advances Share Repurchase Program
Jul 2, 2025

Ajinomoto Co., Inc. has announced the progress of its share repurchase program, which was initially resolved by the Board of Directors on May 8, 2025. As of June 30, 2025, the company has repurchased 14,658,600 shares for a total of JPY 46,613,688,345. This strategic move is part of a larger plan to repurchase up to 50 million shares, with a maximum budget of JPY 100 billion, to be completed by November 30, 2025. The repurchase is being conducted through the Tokyo Stock Exchange and is expected to enhance shareholder value by reducing the number of outstanding shares.

The most recent analyst rating on (JP:2802) stock is a Buy with a Yen3450.00 price target. To see the full list of analyst forecasts on Ajinomoto Co stock, see the JP:2802 Stock Forecast page.

Ajinomoto Co. Advances Share Repurchase Program
Jun 3, 2025

Ajinomoto Co., Inc. has announced the progress of its share repurchase program, which was resolved by the Board of Directors on May 8, 2025. The company repurchased 12,374,900 common shares for JPY 38.27 billion between May 9 and May 31, 2025, as part of a larger plan to buy back up to 50 million shares by November 30, 2025. This strategic move is aimed at optimizing capital structure and enhancing shareholder value, with all repurchased shares set to be canceled.

The most recent analyst rating on (JP:2802) stock is a Buy with a Yen3450.00 price target. To see the full list of analyst forecasts on Ajinomoto Co stock, see the JP:2802 Stock Forecast page.

Ajinomoto Co. Initiates Significant Share Repurchase Program
May 9, 2025

Ajinomoto Co., Inc. announced the repurchase of 9,824,800 of its own shares, aiming to enhance shareholder returns and improve capital efficiency. This move is part of a broader plan to repurchase up to 50 million shares by November 2025, reflecting the company’s commitment to optimizing its capital structure and potentially increasing shareholder value.

Ajinomoto Co. Announces Strategic Share Repurchase Plan
May 8, 2025

Ajinomoto Co., Inc. has announced a plan to repurchase up to 10 million of its own shares, representing 1.01% of its total issued shares, through the Tokyo Stock Exchange’s off-auction trading system. This strategic move, with a maximum cost of JPY 30.15 billion, is part of a broader initiative to repurchase up to 50 million shares by November 2025, aiming to enhance shareholder value and optimize capital structure.

Ajinomoto Co. Initiates Transfer of Head Office Assets
May 8, 2025

Ajinomoto Co., Inc. has announced its decision to transfer its non-current assets, specifically the land and building of its current head office in anticipation of relocating to a new head office in fiscal year 2026. The transfer process will be conducted through a competitive bidding process, with the agreement and transfer scheduled for fiscal year 2025. This strategic move is part of Ajinomoto’s broader operational adjustments and is expected to impact its asset management and future operational efficiencies.

Ajinomoto Co. Announces Major Share Repurchase Plan
May 8, 2025

Ajinomoto Co., Inc. has announced a decision to repurchase up to 50 million of its own shares, representing 5.03% of its total issued shares, with a maximum repurchase cost of JPY 100 billion. This move aims to enhance shareholder returns and improve capital efficiency, with plans to cancel all repurchased shares to optimize the company’s capital structure.

Ajinomoto Reports Increased Sales but Decline in Profits for FY2024
May 8, 2025

Ajinomoto Co., Inc. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 6.3% increase in sales to 1,530,556 million yen. Despite the rise in sales, the company experienced a decline in profit before income taxes and profit attributable to owners of the parent company, primarily due to changes in accounting treatments and a stock split. The company also announced a forecast for the fiscal year ending March 31, 2026, with expected sales of 1,618,000 million yen and a significant increase in profit attributable to owners of the parent company by 70.7%.

Ajinomoto Revises Earnings Forecast Following Subsidiary Sale
Apr 24, 2025

Ajinomoto Co., Inc. has revised its full-year consolidated performance forecast for the fiscal year ending March 31, 2025, due to an impairment loss related to its subsidiary, Ajinomoto Althea, Inc. The company has sold its shares in Althea to Packaging Coordinators Inc., leading to a downward revision of profit attributable to owners by ¥20.1 billion. This strategic move is expected to impact Ajinomoto’s financial results, with extraordinary losses recorded in its non-consolidated performance estimates due to the valuation of stocks of subsidiaries and affiliates.

Ajinomoto Co. Sells Subsidiary Althea to PCI in Strategic Realignment
Apr 24, 2025

Ajinomoto Co., Inc. has decided to sell its subsidiary, Ajinomoto Althea, Inc., to Packaging Coordinators Inc. (PCI) as part of its strategic realignment. This move aligns with Ajinomoto’s Medium-Term ASV Initiatives 2030 Roadmap, focusing on high-growth areas and leveraging proprietary technologies to enhance profitability in the healthcare sector.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025